Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 15/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2607605 | 0.91 | CETP (0.80) | CETPMAPTLMNACEPT1TP53 | |
| SCHEMBL13182119 | 0.91 | KDM4E (0.78) | CETPMAPTLMNACEPT1KDM4E | |
| SCHEMBL13182118 | 0.83 | MAPT (0.76) | CETPMAPTLMNACEPT1KDM4E | |
| SCHEMBL13677062 | 0.82 | CETP (1.00) | CETPMAPTCEPT1TP53RXFP1 | |
| SCHEMBL2607748 | 0.81 | KDM4E (0.85) | MAPTLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL4534132 | 0.79 | CETP (0.86) | CETPMAPTCEPT1TP53RXFP1 | |
| SCHEMBL1734039 | 0.78 | CETP (0.79) | CETPMAPTCEPT1POLBTP53 | |
| SCHEMBL13054292 | 0.78 | MCHR1 (0.64) | CETPMAPTLMNACEPT1POLB | |
| SCHEMBL2245308 | 0.78 | MAPT (0.81) | CETPMAPTKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL3749992 | 0.77 | MCHR1 (0.63) | CETPMAPTLMNACEPT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969342-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | CETP 1943/4885MAPT 4129/4885LMNA 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.